Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Leases: 2019-2024

Historic Current Leases for Amphastar Pharmaceuticals (AMPH) over the last 6 years, with Dec 2024 value amounting to $6.8 million.

  • Amphastar Pharmaceuticals' Current Leases rose 85.96% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 85.96%. This contributed to the annual value of $6.8 million for FY2024, which is 74.19% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Current Leases stood at $6.8 million, which was up 74.19% from $3.9 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Current Leases ranged from a high of $6.8 million in FY2024 and a low of $3.0 million during FY2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Current Leases value was $3.9 million (recorded in 2023), while the average stood at $4.6 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Current Leases dropped by 11.17% in 2021 and then skyrocketed by 74.19% in 2024.
  • Amphastar Pharmaceuticals' Current Leases (Yearly) stood at $3.4 million in 2020, then decreased by 11.17% to $3.0 million in 2021, then climbed by 0.70% to $3.0 million in 2022, then spiked by 30.07% to $3.9 million in 2023, then spiked by 74.19% to $6.8 million in 2024.